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Abstract
SSc is a multisystem disease characterized by an unpredictable course, high mortality and resistance to
therapy. The complexity and severity of SSc is a growing burden on the health-care systems. As a result,
researchers are seeking new therapeutic strategies for effectively managing these patients. Disease regis-
tries are used to support care management efforts for groups of patients with chronic diseases and
are meaningful to capture and track key patient information to assist the physicians in managing patients.
For these reasons, SSc surveys, research associations and consortiums are pivotal to conduct ongoing
research and data collection to enhance disease knowledge and support research projects. Currently,
there are several national SSc registries in the UK, Germany, USA, Canada, Brazil and Australia. There is
also an international registry established by the European League Against Rheumatism scleroderma trial
and research (EUSTAR) called minimal essential data set (MEDS) Online, which collects data from over
8000 patients from 92 centres worldwide, including 21 European centres and 9 centres outside Europe. By
collecting, analysing and disseminating data on disease progression and patient responses to long-term
disease management strategies, registries help to improve understanding of the disease and keep medical
professionals up to date on the latest advances.
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Introduction
SSc is a multisystem disease characterized by an unpre-
dictable course, high mortality and resistance to therapy.
The complexity and severity of SSc is a growing burden
for all health-care systems. As a result, researchers are
seeking new therapeutic strategies for effectively mana-
ging these patients.
A registry is just one component of a comprehensive
disease management strategy. A systematic and com-
prehensive approach to disease management includes
a range of interventions, such as case management,
physician feedback, clinical information systems to track
patient care, adoption of clinical practice guidelines, out-
reach to patients who need to come in for care and a
focus on patient self-management skills.
Disease registries are used to support care manage-
ment efforts for groups of patients with chronic diseases
and are meaningful to capture and track key patient
information to assist the physicians in managing patients.
For these reasons, SSc surveys, research associations
and consortiums are pivotal to conduct ongoing research
and data collection to enhance disease knowledge and
support research projects. The present report provides
an overview of the national and international SSc registries
that have been created all over the world.
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European national registries
UK registry
A national UK register, started in 1995, comprises details
on >3000 UK cases of SSc. It identifies patients that may
be included in clinical trials and is essentially a
cross-sectional database with information on living indi-
viduals. Specifically, basic clinical and demographic data
were collected. The register was set up as a paper-based
system, underpinned by grant support from Arthritis
Research UK to fund data entry into an electronic data-
base and collation of the paper hard copy datasheets.
Although it has been valuable in practice, this initiative
has also identified a number of problems inherent with
initiation of a long-term registry. First, the amount of clin-
ical information has proved not completely sufficient and
the absence of longitudinal data has been a major limita-
tion. In addition, the ability to utilize data has been re-
stricted over recent years by the lack of study-specific
approval, which was not required initially at the time
of setting up the database. Thus, although the concept
remains valid, it has not achieved the utility and product-
ivity of similar web-based systems, such as the more
recent European League against Rheumatism (EULAR)
Scleroderma Trials and Research (EUSTAR) group
database.
These aforementioned limitations have also been
addressed by an initiative termed Scleroderma Cohort
(SMART)—data and sample collection and analysis. It
will involve establishment of a simple database, storing
coded basic demographic and clinical information about
the majority of SSc patients in the UK. This will include a
prospective record of clinical data to elicit disease course
and predictors of outcome in SSc. Collection of blood
samples for autoantibody, biomarker and DNA analysis
will be done as part of the project, which also facilitates
integration with other international projects. The comple-
mentary approach that we have followed is the establish-
ment of an in-house database of cases seen in the Royal
Free Hospital (RFH) SSc centre. The RFH SSc cohort rep-
resents one of the largest and best characterized
single-centre cohorts of SSc patients. Good-quality clin-
ical information on >2200 cases has been recorded on
the database. The information data set collected for this
cohort is centred upon the information required to deter-
mine the SSc International Severity Score. In addition,
SSc functional data are routinely recorded and instru-
ments such as the GI questionnaire can be incorporated.
Essentially, this database reflects clinical practice in our
centre. All patients consent to enrol through provision for
biological sample collection and this is linked to ongoing
clinical research protocols within the department.
Reasons why this cohort has been so productive include
the consistent nature of patient evaluation with
well-trained observers assessing skin score and other
disease-specific parameters as well as the availability of
robust autoantibody data. Having a manageable data set
and the ability to perform quality control through reference
to primary source documents, such as clinical notes,
ensures that data collection is not burdensome and the
quality is good. The database is maintained on an
Microsoft Access platform and additional domains can
be added relatively easily. It is stored on a firewalled and
networked university server with all data being anon-
ymized. This can in turn link with laboratory databases
for DNA, serum, plasma and skin biopsies. It thus essen-
tially represents and provides a single-centre biobank that
can be used as the starting point for many clinical pro-
jects. It also links with systematic databases maintained in
pulmonary hypertension and interstitial lung disease and
these links have permitted serial exploration of outcome.
The large number of publications underpinned by the
RFH SSc cohort is a measure of its success. Recent ana-
lyses of outcome in both major subsets over a decade are
very informative [1], following on from the first studies that
looked at predictors of survival [2], which have subse-
quently been validated in other cohorts. The utility of
skin score change in predicting burden of disease and
outcome has also been demonstrated [3]. Links to bio-
logical samples have proved very valuable and underpin
projects to systemically examine candidate biomarkers in
SSc. Renal crisis is a rare complication and so
single-centre cohorts can be used to assess outcome
and current treatment protocols [4]. This has been a com-
plementary approach to the national study in France.
To allow the UK initiative to develop and realize its
potential, we have recently obtained long-term ethical ap-
proval covering data and sample collection and transfer,
which also permits the development of collaboration with
EUSTAR, which has followed the UK lead and developed
a web-based database.
German registry
The German Network for Systemic Scleroderma (DNSS)
was founded in 2003 with a grant by the German Federal
Ministry of Education and Research (BMBF). There is an
intensive collaboration of different subspecialties includ-
ing dermatologists, rheumatologists, pulmonologists
and nephrologists. Starting with initial 21 centres, the net-
work enhanced and expanded in the course of 6 years
with altogether >40 clinical centres at present. The net-
work also includes five centres concentrating on certain
organ-specific involvements.
A disease- and organ-specific questionnaire was
designed in 2003 and then adapted in the years since
depending on gain in experience. It includes basic infor-
mation on gender, date of birth, height, weight, family his-
tory of inflammatory rheumatic diseases and symptoms of
visceral organ involvement (heart, lung, gastrointestinal
tract, kidney, musculoskeletal system and nervous
system), as well as characteristic laboratory data such
as ANAs, ESR and CK serum levels. Skin involvement
was evaluated using the modified Rodnan skin score
(mRSS): to ensure standardized and correct performance
of skin scoring. Participants of the involved clinical centres
were trained several times by attending the EUSTAR skin
score courses. Furthermore, information on physical as
well as on systemic therapies was registered, including
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vasoactive substances, CSs, immunosuppressive drugs
and others. Patients are examined and registered yearly
to measure the course of disease between initial patient
registration and yearly follow-up visits, and to determine
special indicators for disease progression. To provide
consistency of registered data, a set of definitions for
each item on the registration form, and recommendations
for organ-specific diagnostic procedures were prepared.
The network also provided the infrastructure to collect
blood and tissue samples.
To ensure the detection of disease heterogeneity, the
registry defined five different SSc subsets, i.e. lcSSc,
dcSSc (according to the ACR criteria), overlap syndrome,
undifferentiated SSc with features of scleroderma and
SSc sine scleroderma.
Up to date, the DNSS contains data of more than 2500
patients. Of these, the most frequent subset is the limited
cutaneous form (48.2%), followed by the diffuse cutane-
ous form (31.6%), the overlap syndrome (10.5%) and the
undifferentiated form (7.4%). SSc sine scleroderma was
found only in 0.8% of all registered patients. Our nation-
wide female : male ratio ranged from 3.1 : 1 in dcSSc to
6.5 : 1 in lcSSc. The data revealed that female patients
were on average older than male patients and that a
family history of rheumatic diseases was reported by
nearly 17% of all patients, being significantly associated
with a lower mean age and earlier disease onset of RP,
skin involvement and internal organ involvement [5].
Regarding visceral organ involvement, our data analyses
showed that patients suffering from the diffuse form of
SSc show the highest frequencies of pulmonary fibrosis
(62.9%), pulmonary hypertension (20.2%), kidney (15.9%)
and heart involvement (20%). In contrast, gastrointestinal
involvement did not show significant differences between
the subsets of dcSSc (65.2%) and lcSSc (60.7%).
Meanwhile, follow-up data for 1 year are available from
1208, for at least 2 years from 642, 3 years from 336 and
at least 4 years from 159 patients. After 1 year, a signifi-
cant increase in the frequency of nearly all visceral organ
manifestations (pulmonary hypertension, lung fibrosis and
oesophagus) was detectable, while after 2 years an
increased occurrence of pulmonary arterial hypertension
(PAH), lung fibrosis, oesophagus, kidney involvement and
heart involvement was found.
Further statistical analyses facilitated an overview of the
prescription of different immunosuppressive agents and
the development of recommendations for diagnostic as
well as therapeutic procedures [6, 7]. Besides the particu-
lar importance of the networks for clinical trials and epi-
demiological/descriptive analyses, the DNSS provides
close interdisciplinary cooperation and intensified care
for patients with SSc.
American registries
University of Pittsburgh Scleroderma Databank
The University of Pittsburgh Scleroderma Databank was
the first SSc registry initiated in 1980. It is the prototype of
all registers in SSc as it includes a comprehensive initial
evaluation, standard SSc examination, laboratory studies,
an SSc HAQ, yearly serum samples and in more recent
years DNA samples. Most importantly, it includes a com-
prehensive annual to biannual follow-up of patients, which
resulted in a very high (93%) accountability of the patients.
Since 2002, when additional institutional board review
requirements and costs made this intensive follow-up im-
possible to maintain, the survival outcome is maintained
through the Social Security and National Death Index. This
databank now has >4000 patients with >30 years of
follow-up data. It has resulted in >150 publications relat-
ing to the epidemiology, natural history, risk factors, out-
comes and survival in all aspects of SSc. Many of these
studies are sentinel papers, whose initial findings are now
being confirmed by the newer registries from around the
world.
Pulmonary hypertension registry
Pulmonary Hypertension Assessment and Recognition of
Outcomes in Scleroderma (PHAROS), is a multicentre
registry looking at patients with pre-PAH and definite pul-
monary hypertension. There are 20 sites throughout the
USA that enter patients and follow them every 6 months
with patient and physician data and objective studies.
The entry criteria for the pre-PAH patient group includes
those who are at high risk for developing PAH including
a DLCO <55% of predicted, a FVC%/DLCO% ratio >1.6 or
an echocardiographic estimated pulmonary artery pres-
sure of >40 mmHg. These patients complete question-
naires about dyspnoea (University of California San
Diego Dyspnoea Index), function (SHAQ) and quality of
life (SF-36) every 6 months. They have a yearly physician
evaluation for symptoms, examination and medication,
and hospitalization history. They also have yearly PFTs,
echo, 6-min walk tests and laboratory tests as part of
their standard of care. Any patient who has a change in
symptoms or findings is catheterized to determine
whether they have developed pulmonary hypertension.
Patients who have a positive right heart catheterization
showing a mean pulmonary artery pressure >25 mmHg
are defined as definite pulmonary hypertension. They are
then divided into WHO groups according to the Dana
point meeting. Group 1 with PAH; Group 2 with pulmonary
venous hypertension or diastolic dysfunction (systolic
failure or non-scleroderma heart disease patients are
excluded); or Group 3 with pulmonary hypertension
secondary to interstitial lung disease. Patients are fol-
lowed at least every 6 months with symptoms, question-
naires, 6-min walk and BNP. Other tests are yearly.
After 2.5 years of patient entry, 250 patients with
pre-PAH have been registered. Of the 206 patients who
have had at least 1 year of follow-up, 14 have proceeded
to definite PAH and 5 developed Group 2 pulmonary
venous hypertension. Thus, the time to evolution to PAH
for these patients was 22% at 2 years. Of the 133 PH
patients entered, only 69% of them had PAH; 24 (or
18%) had pulmonary venous hypertension and 17 (13%)
had PH from interstitial lung disease. During the follow-up,
a 91% 2-year survival could be achieved.
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This prospective study’s objective is to identify the pa-
tients at highest risk for developing PH and to determine
the best risk factors to identify them and to determine the
outcome of aggressive treatment of these early diagnosed
patients. It is critically important for us to make this diag-
nosis as early as possible in order to treat these patients
aggressively and prevent severe heart failure. Taken to-
gether, this procedure will facilitate early diagnosis and
the treatment will greatly improve the survival of the
most common cause of SSc-related deaths.
Canadian registry
In 2003, 17 rheumatologists from across Canada created
the Canadian Scleroderma Research Group (CSRG) with
the aim of increasing the capacity to perform high-level
SSc research in Canada. The Group includes scientists
from both inside and outside the field of SSc (rheumatolo-
gists, cardiologists, respirologists, gastroenterologists,
dermatologists, dentists, psychologists, basic scientists,
epidemiologists and statisticians) and new trainees inter-
ested in pursuing SSc research (including 22 summer stu-
dents and 15 graduate trainees who have worked with
CSRG mentors on various projects in the past 4 years
alone). As of 1 March 2010, the CSRG had enrolled a
total of 1095 patients, of which 86% were females,
mean age was 55 years, mean disease duration since
the onset of their first non-Raynaud’s symptoms was
11 years and 59% had limited disease. Funding has
come from multiple sources including grants from the
Canadian Institutes of Health Research (CIHR), the
Scleroderma Society of Canada, Cure Scleroderma
Foundation, Scleroderma Society of Ontario,
Scle´rodermie Que´bec, as well as unrestricted grants
from several Canadian pharmaceuticals companies.
Detailed patient data collected yearly are entered and
stored via the web in a central database. Indeed, the
easy availability of high-quality and detailed patient-level
data has stimulated numerous ideas for projects over and
above our initial objectives. The network was interested in
measurement and started with a demonstration of the
value of office capillaroscopy and then reported on the
reliability of widefield microscopy in SSc (Hudson et al.
2010, data not published). Other measurement projects
have included the validation of health-related quality of
life instruments in SSc [8, 9], including the SF-36 [9] and
the World Health Organization Disability Assessment
Schedule II [10]. The participating centres also looked at
correlates of health-related quality of life [11–13], were
interested in measurement of disease activity, severity
and damage in SSc [14] and have a number of studies
ongoing in these areas [15–16]. In addition, disease clas-
sification is a major focus [10] in combination with work in
various areas including depression [17–20], work disability
[21], pain [22] and pruritus [23]. Moreover, the data were
used to produce robust estimates of the economic costs
of SSc [24, 25], helped to develop an interest in nutritional
aspects of the disease, showed that malnutrition is
common in SSc [26] and that serum albumin is not a
good marker for malnutrition [27]. There were very few
laboratories doing SSc work in Canada before the estab-
lishment of the CSRG. At present, projects are ongoing in
six different laboratories, only one of which had prior ex-
perience with SSc. It must, however, be noted that the
CSRG relies on the goodwill of the participating rheuma-
tologists to collect and record all the data that we require
yearly.
Brazilian registry
As there were no large studies analysing disease pat-
terns of SSc in the heterogeneous Brazilian population,
the Brazilian Society of Rheumatology organized the
GEPRO, the Pronuclear Project SSc Study Group. A
common protocol of investigation (including demographic,
clinical and immunological aspects) was designed and
applied to SSc patients in 28 university centres from dif-
ferent geographical areas all over Brazil in the period be-
tween 2003 and 2006. A series of 1139 patients, 508 with
lcSSc (44.6%), 504 with dcSSc (44.2%), 73 with overlap
syndromes (6.4%) and 54 with SSc sine scleroderma
(4.8%) was included. Most patients were females [996
(87.4%)]. There were 740 Caucasian (65%), 390
African-Brazilian (34.2%, originating from white and black
miscegenation) and 9 Japanese-Brazilian (0.8%) patients.
Calcinosis was present in 19.2% of the patients, while leu-
comelanodermia was observed in 45.8% and
telangiectasia in 47.2% of the patients. Fingertip pitting
scars were referred by 62.9%, and 37.5% presented
previous ischaemic ulcers. Inflammatory polyarthralgia
was referred by 35.6% of the patients, while arthritis
was observed in 39.7% and tendon friction rubs in
11.2%. Dysphagia was referred by 62.2% of the patients;
barium-contrasted oesophagram showed reduced motility
in 68.2% and gastro-oesophageal reflux in 41.7%; 3.2%
of the patients had to be submitted to GER surgery.
Intestinal malabsorption was present in 4.8% and anal
incontinence in 3.6%. Dyspnoea was referred by 55%
of the patients, with bibasilar crackles in 27.5% and
an altered chest X-ray in 32.7%; pulmonary function
test was abnormal in 52%, with an altered chest high-
resolution CT in 45.2%. Clinical arrhythmia was present
in 9% of the patients, pericardial effusion in 5.8%, angina
in 7.4%, myocardial infarction in 6.7% and congestive
heart failure in 9.4%. Echocardiographic signs of
pulmonary hypertension were observed in 13.3% of
the patients. Scleroderma renal crisis was diagnosed in
3.4% of the patients.
Total skin score was significantly higher in males when
compared with females (P< 0.0001). Male gender was
statistically associated with higher total skin score
(P< 0.0001). Leucomelanodermia (P= 0.025), flexion con-
tractures (P< 0.0001), pulmonary rales at auscultation
(P= 0.017), smoking habit (P< 0.0001) and scleroderma
renal crisis (P= 0.003) were also more frequent in males,
while arthritis (P= 0.001) and ACAs (P= 0.008) were more
frequent in females. Caucasian patients presented statis-
tically significant association with pruritus (P< 0.0001),
leucomelanodermia (P< 0.0001), calcinosis (P= 0.009),
dysphagia (P= 0.045), higher pulmonary artery systolic
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pressure at echo-doppler (P= 0.004) and ACAs
(P< 0.0001). African-Brazilian patients presented associ-
ation with skin ulcers (P= 0.007), tendon friction rubs
(P= 0.034), flexion contractures (P= 0.045), smoking
habit (P= 0.044) and anti-Scl-70 (P< 0.0001). ANA, deter-
mined in commercial HEp-2 cells, was positive in 82.9%
of the tested patients. ACAs were detected in 14.4% and
anti-Scl-70 in 19.1% of the patients. The most frequently
observed ANA patterns were speckled (41.8%), nucleolar
(14.5%), centromeric (14.4%) and homogeneous (10.4%).
ACA showed a significant statistical association with lim-
ited SSc (P< 0.001), calcinosis (P= 0.001), anal incontin-
ence (P= 0.033), nervous system involvement (P< 0.001)
and lower mRSS (P< 0.001). The presence of anti-Scl-70
antibodies was associated with diffuse SSc (P< 0.001),
pruritus (P= 0.004), pigmentary disturbances (P< 0.001),
digital microulcerations (P= 0.016), arthritis (P= 0.013),
tendon friction rubs (P= 0.009), flexion contractures
(P< 0.001), dyspnoea (P< 0.001), interstitial lung involve-
ment (P< 0.001) and higher mRSS (P< 0.001). Other
autoantibodies were positive in 17.5% of the tested pa-
tients; the most frequently observed ones were anti-SSA/
Ro (5.7%), anti-U1-RNP (5.1%) and aCL (3.4%). There
were no specific manifestations associated with these
antibodies.
The analysis of this large Brazilian cohort showed that
male gender, African-Brazilian ethnicity, diffuse SSc and
positive anti-Scl-70 antibodies are associated with a more
severe disease. Oesophageal and lung involvement were
the dominant clinical manifestations and renal crisis was
quite uncommon in the series. After the implementation of
this national database, most rheumatology units in the
main university centres in Brazil have an SSc outpatient
clinic, and basic and clinical research focusing on specific
SSc aspects in the heterogeneous Brazilian population
can now be performed.
Oceania national registries
Australian Scleroderma Special Interest Group
Scleroderma Screening Programme
The Australian Scleroderma Special Interest Group (ASIG)
was established in 2007 and is a nationwide collaboration
currently underway in more than a dozen centres. The
programme aims to increase screening for PAH in patients
with SSc and mixed CTD. It aims to provide a screening
algorithm, to establish a web-based database, to support
compliance with guidelines as well as to stimulate sclero-
derma research in Australia. The programme provides
yearly reviews including echocardiography and lung func-
tion testing and provides a comprehensive report to the
treating doctor. To date, >900 patients have entered the
programme on an ongoing basis, with age range 18–88
years, 88% females, 66% with limited and 26% diffuse
disease. The prevalence of PAH has been shown to be
11% using right heart catheterization as the gold standard
for diagnosis with disease duration of 5.4–18 years and
64% in WHO Class 3 and 10% in WHO Class 4 at diag-
nosis, hence it will be important over time to see if the
screening programme allows earlier diagnosis at
an earlier WHO class with potentially better
prognosis. Tracking patients on PAH therapy over time
is facilitated. Twenty-four per cent of the cohorts
have had significant interstitial lung disease. It has been
estimated using Australian prevalence and incidence
figures that 25% of the Australian scleroderma popula-
tion has been enrolled. Research projects including utility
of BNP, genome-wide scanning and mycophenolate in
scleroderma-ILD are underway.
International registries
EUSTAR online database
In order to foster awareness, understanding and research
of scleroderma and its care and management throughout
Europe, the EUSTAR group (www.eustar.org) was inaugu-
rated under the auspices of the EULAR standing commit-
tee on international clinical studies including therapeutic
trials (ESCISIT) and has established a prospective multi-
centre SSc cohort.
EUSTAR was started in 2003 and the SSc database
launched in 2004 [28]. It represents a multinational, pro-
spective and open SSc cohort. Participating centres
enter the minimal essential data set (MEDS) with all con-
secutive consenting patients who fulfil the ACR
classification criteria for SSc [29]. Scleroderma subsets
are classified as diffuse SSc if skin thickening extends
proximal to the elbows and knees or includes the trunk,
and as limited SSc if confined to distal extremities and
face [30]. The MEDS was designed in consensus by the
EUSTAR members and covers demographic aspects,
disease duration, organ involvement and laboratory
data [31]. Disease activity is calculated as a composite
score from MEDS parameters according to the prelimin-
ary index for SSc as a whole, proposed by the ESSG
and detailed elsewhere [32]. Annual follow-up examin-
ations are implemented. To improve long-term data ana-
lysis and tracking of patients suitable for clinical and
basic research trials, an online database was launched
in June 2006 (MEDS Online). Simultaneously, the MEDS
was extended by items such as right heart catheter
measurements, medication and a centre-based biobank,
which collects sera, tissue samples and DNA
material. As of March 2010, MEDS Online follows a
total number of 8147 patients with SSc. A total of 92
centres from 21 European and 9 non-European countries
have initiated online status. Each EUSTAR member is
strongly invited to submit research proposals that are
subject to peer review by the EUSTAR scientific
committee.
The MEDS Online database uses a very intuitive and
easy to use web interface. A series of web forms are ac-
cessible through a side menu. The forms contain
patient-specific data that are sorted according to dates
of patient visits where applicable in order to allow the
documentation of static and follow-up data. Users can
also download printable documentation of their patients’
visit data for their files. This printable visit-based
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documentation also contains an overview of the evolution
of the patient’s clinical outcome parameters over past
visits. The MEDS Online database provides unrestricted
online data search and export capabilities that allow each
centre to use and export its own data.
In addition, the system provides for each centre a full
overview of its biosamples stored locally. These features
also render the MEDS Online database a useful tool for
centre-initiated research purposes. Access to the MEDS
Online database is only granted following local ethics
committee approval. Data monitoring includes automated
online algorithms to identify double entries, missing data
and plausibility checks. Most data entry fields feature a
pop-up window providing assistance, definitions and
coaching material. The centres were and will be coached
on a regular basis and during EUSTAR courses on how to
fill out the forms. Coaching sessions included the ACR
classification of SSc, definitions of the subgroups and
the activity score. Standardized teaching sessions
included the documentation of the mRSS at the bedside,
following two teach the teachers sessions held in 2004
and 2005 [33]. The definitions of the MEDS parameters
and video coaching material are also available on the
EUSTAR web site.
The MEDS Online database also features easy extend-
ibility for additionally small- or large-scale scientific pro-
jects either within EUSTAR itself or in collaboration with
industrial partners. Among the many ongoing EUSTAR
projects, several analyses have been completed.
EUSTAR gained insight into factors that are associated
with particular organ manifestations and thus potentially
also with the disease process [34, 35]. By focussing on
age at onset of RP, gender and autoantibodies, this pro-
ject examined whether the dichotomy into limited and dif-
fuse cutaneous subsets of SSc is the best way to capture
the disease and its organ manifestations, or whether other
clinical or laboratory parameters may be more appropri-
ate. While the dcSSc subset was found to be associated
with more prevalent internal organ complications, an
antibody-based classification added independent infor-
mation in predicting some scleroderma manifestations.
In fact, autoantibody status in this EUSTAR analysis ap-
peared more closely associated with some clinical mani-
festations than were SSc subsets [31].
Heart involvement in SSc may be life threatening.
Another EUSTAR analysis focused on left ventricular dys-
function and found a prevalence of 5.4%. Independent
risk factors for its presence were age, male gender, digital
ulcerations, myositis and lung involvement [36].
Large geographical variations in SSc prevalence and
incidence have been described. EUSTAR documentation
covers a broad geographical area, allowing the analysis
of geographical variation among different SSc presenta-
tions, autoantibody associations and gender ratio, which
could help in identifying genetic or environmental factors
in the aetiology of the disease. The main EUSTAR
finding is that there was no clear regional trend with
regard to key factors thought to influence organ involve-
ment, such as clinical SSc subsets, gender and mRSS.
In addition, there was no geographical association be-
tween organ manifestations related to ambient tempera-
ture such as RP. There was also no association between
geographical longitude or latitude and age at disease
onset [37].
A very recent analysis of SSc-related mortality indicates
that the disease-specific mortality is still high in the cur-
rent era despite the possibility to prevent or mitigate some
organ complications by new pharmacological interven-
tions. Most patients die from SSc-related complications
rather than from other causes. Renal involvement,
pulmonary complications, skin induration and age at
SSc onset predict the excess mortality [38].
Conclusions
Disease registries are large, often multinational observa-
tional databases that collect clinical data on patients
with SSc. By collecting, analysing and disseminating
data on disease progression and patient responses to
long-term disease management strategies, registries
help improve disease understanding and keep medical
professionals up to date on the latest advances [39–41].
TABLE 1 Strengths and limitations of registry-based studies
Strengths Limitations
Longitudinal data of large sample size
Track the natural history of the disease over time
Track the long-term effectiveness and safety of
treatments
Enable time-to-event analysis
Allow subset analyses
Essential information source for rare diseases
Provide generalizable evidence
Provide evidence of the effectiveness of treatments in
the real world
Generate new hypotheses for further investigation
Assessment or treatment criteria may be not uniform—
potential for selection bias
Patients seen in diverse centres/countries
Lack of data verification
May not have complete data/follow-up
Patients are not monitored as rigorously as in randomized con-
trolled studies—the rate of some events may be
underestimated
Data are collected anonymously—avoid duplicate records on
same patient
No control population
Potential for industry influence on analytical methods
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TABLE 2 Patients characteristics and main findings of SSc registries
Patients characteristics
UK
registry DNSS
Pittsburg
Scleroderma
Databank PHAROS
CSRG
registry
Brazilian
registry
(GEPRO)
ASIG
scleroderma
screening
programme
EUSTAR
MEDS
Year 1995 2003 1980 – 2003 2003 2007 2004
Patients enrolled >2200 >2500 >4000 250 1095 1139 900 8147
Gender
Male, % – – – – 14 12.6 12 –
Female, % – – – – 86 87.4 88 –
Female to male ratio – 3.1 : 1 – – – – – –
dcSSc
6.5 : 1
lcSSc
Mean age, years – – – – 55 – –
Mean disease duration, years – – – – 11 – –
Subsets
dcSSc, % – 31.6 – – – 44.2 26 –
lcSSc, % – 48.2 – – 59 44.6 66 –
Overlap, % – 10.5 – – – 6.4 – –
Undifferentiated, % – 7.4 – – – – – –
Sine scleroderma, % – 0.8 – – – 4.8 – –
Lung involvement
Pulmonary fibrosis, % – 62.7 dcSSc – – – 24 –
Pulmonary hypertension, % – 20.2 dcSSc – – – 13.3 11 –
Renal involvement, % – 15.9 dcSSc – – – 3.4 – –
Heart involvement, % – 20.9 dcSSc – – – – –
Arrhythmias, % – – – – – 9 – –
Pericardial effusion, % – – – – – 5.8 – –
Angina, % – – – – – 7.4 – –
Myocardial infarction, % – – – – – 6.7 – –
Gastrointestinal involvement, % – 65.2 dcSSc – – – – –
60.7 lcSSc
Dysphagia, % – – – – – 62.2 – –
Oesophageal dysmotility, % – – – – – 68.2 – –
GE reflux, % – – – – – 41.7 – –
Intestinal malabsorption, % – – – – – 4.8 – –
Anal incontinence, % – – – – – 3.6 – –
Articular involvement – – – – – – –
Polyarthralgia, % – – – – – 35.6 – –
Arthritis, % – – – – – 39.7 – –
Tendon friction rubs, % – – – – – 11.2 – –
Calcinosis, % – – – – – 19.2 – –
DU – – – – – – –
Ongoing DU, % – – – – – 62.9 – –
Previous DU, % – – – – – 37.5 – –
Leucomelanodermia, % – – – – – 45.8 – –
Telangiectasia, % – – – – – 47.2 – –
Autoantibodies – –
ANA, % – – – – – 82.9 – –
Speckled, % – – – – – 41.8 – –
Nucleolar, % – – – – – 14.5 – –
Centromeric, % – – – – – 14.4 – –
Homogeneous, % – – – – – 10.4 – –
ACA, % – – – – – 14.4 – –
Scl-70, % – – – – – 19.7 – –
Others – – – – – – –
Anti-SSA/Ro, % – – – – – 5.7 – –
Anti-U1-RNP, % – – – – – 5.1 – –
aCL, % – – – – – 3.4 – –
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Well-characterized cohorts of SSc patients are the
cornerstone of clinical research that addresses important
topics such as outcome assessment and the potential ef-
ficacy of current treatment protocols. Although cohort stu-
dies cannot provide the same level of evidence as
prospective controlled trials, they are a valuable clinical
resource. A cohort of patients derived from a disease
registry addresses different research questions from
those of a simple practice-based cohort, which is typically
comprised of consecutive patients seen in a particular
practice setting, or consecutive patients who meet certain
predefined case criteria and who are then followed over
time according to a set protocol for particular outcomes.
This distinction between a registry-based population and
a restricted cohort may have many practical implications.
The registry population includes samples from many
sources and therefore cannot control the type or fre-
quency of laboratory testing of patients, having to rely
on community standards of care for these data.
Although this may result in incomplete information on
some cases, the trade-off is that many more cases can
be included and referral bias is diminished. Prevalence,
incidence and survival data can then be derived for the
study population, followed over time to determine
temporal trends, and extrapolated to larger populations
of similar demographic characteristics. A summary of
strengths and limitations of registry-based studies is
shown in Table 1. The limitations of disease registries
may be overcome considering possible confounding fac-
tors that may distort the results and reducing possible
sources of bias (covariate adjustment, case control
matching, etc.) with a rigorous database design and
data collection, and with training courses on standardized
criteria of patient assessment and distributing coaching
materials on data entry. Unfortunately, it was impossible
to compare registries, due to non-uniformity of the data
presented in this report (Table 2).
In conclusion, national registries are very useful to
understand the prevalence/incidence of SSc in single
countries, but international registries remain of invaluable
utility to understand the overall behaviour of SSc and
its clinical features as well as being a solid base for
large-scale genetic, clinical and basic studies [42].
Rheumatology key messages
. Registries improve disease understanding and keep
medical professionals up to date on the latest
advances.
. International registries remain of invaluable utility
to understand the overall behaviour of SSc and its
clinical features.
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